中文摘要：

以2株放线菌无活性野生株M15（海洋）和M13（陆地）为原始菌,利用核糖体工程抗性筛选技术,通过对M15的链霉素、新霉素、利福平、庆大霉素抗性筛选,得到抗性突变株共63株,经对M13的链霉素抗性筛选,得到链霉素抗性突变株18株。其中,6株M15突变株在活性测试中示有抗肿瘤活性,100μg/mL样品对K562细胞的抑制率大于30%,活性最强的1株新霉素8μg/mL抗性突变株CTM154-8N抑制率高达93.3%,而从M13突变株中没有发现活性突变株。

英文摘要：

M15（marine-derived） and M13（terrestrial）,two wild-type actinomycete strains without antitumor activity,were used as initial strains in present study.By selecting on drug-containing plates according to the method for obtaining drug-resistant mutant in ribosome engineering,total 63 mutants resistant to a drug,streptomycin,neomycin,rifampicin or gentamicin,were obtained from M15 and total 18 of streptomycin-resistant mutants were obtained from M13.In present bioassay by MTT method,both crude samples from M15 and M13 did not show any inhibitory effect on K562 cells even at the 1000 g/mL of high concentration.However,among the mutants obtained,six mutants from M15 were bioactive on K562 cells.Crude samples from the six mutants inhibited the K562 cells with inhibition rates over 30% at the 100 μg/mL.Among them,the strongest one from CTM154-8N,a mutant resistant to 8 μg/mL neomycin,attained to the highest inhibition rate of 93.3% at the 100 μg/mL.On the other hand,the bioactive mutant with antitumor activity could not be found from the 18 str mutants of M13.